知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

927 records (took 0.039 seconds)

    Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction
    43.
    发明授权
    Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction 有权
    HIV GP120中的β20-21环的缺失暴露CD4结合位点以改善抗体结合和抗体诱导

    公开(公告)号：US09266928B2

    公开(公告)日：2016-02-23

    申请号：US14089460

    申请日：2013-11-25

    Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Services

    Inventor： Ira Berkower

    IPC: C07H21/04 ,  A61K39/21 ,  C07K14/005 ,  C07K16/10 ,  A61K39/12 ,  A61K39/00

    CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/6075 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/16122 ,  C12N2740/16134

    Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1.

    Abstract translation: 本文公开了分离的免疫原，包括变体gp120多肽。 在一个实例中，变体gp120多肽包括根据HXB2编号在gp120的残基419和434之间的第四保守环（C4）的至少8个连续残基的缺失。 还提供了编码公开的分离的免疫原的分离的核酸分子。 在一个实例中，分离的核酸分子还包括编码乙型肝炎表面抗原或其变体的核酸分子。 还公开了包括分离的免疫原的组合物，包括变体gp120多肽。 在一些实例中，组合物还包括载体蛋白，例如乙型肝炎表面抗原或其变体（天然或重组）。 还提供病毒样颗粒，包括任何公开的分离的免疫原或组合物。 还公开了这些变体gp120多肽和编码变体多肽的核酸的用途，例如诱导对HIV-1的免疫应答。

    COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS
    44.
    发明申请
    COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS 有权
    用于预防和/或治疗HIV-1病毒感染的组合物

    公开(公告)号：US20160031943A1

    公开(公告)日：2016-02-04

    申请号：US14870287

    申请日：2015-09-30

    Applicant: Patrice DEBRE ,  Vincent VIEILLARD

    Inventor： Patrice DEBRE ,  Vincent VIEILLARD

    IPC: C07K7/08 ,  G01N33/569

    CPC classification number: C07K7/08 ,  A61K39/00 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K14/005 ,  C07K16/1063 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2469/20

    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

    Abstract translation: 本发明涉及包含以下式（I）的抗原肽的免疫原性组合物：Nt-S-X1-X2-X3-K-X4-Ct（I）[SEQ ID No.1]，其中-Nt由 具有0至50个氨基酸长度的肽，-Ct由长度为0至50个氨基酸的肽组成，每个X1至X4由氨基酸残基组成，其中：（i）X1表示特异性 氨基酸W或（ii）X1表示除W以外的任何氨基酸残基， - （i）X2表示特定氨基酸S或（ii）X2表示除S以外的任何氨基酸残基，（i）X3表示特定氨基酸 N或（ii）X3表示除N以外的任何氨基酸残基， - （i）X4表示特异性氨基酸S或（ii）X4表示除S以外的任何氨基酸残基，条件是 - 四个氨基酸 残基X1，X2，X3和X4表示其各自含义（i）中定义的特定氨基酸，X1至X4中的剩余氨基酸残基表示除t之外的任何氨基酸残基 其含义（i）中定义的特异性氨基酸残基用于预防和/或治疗HIV-1病毒感染个体。

Patent Agency Ranking